STAT3 and chronic myelogenous leukemia, BCR-ABL1 positive: This study aimed to investigate STAT3-mediated nilotinib resistance and the possible mechanisms of re-sensitization to it, by analyzing various cellular responses and metabolic reprogramming in CML cells.